JBNI's Bioprin Demonstrates Anti-H. Pylori Results, A Known Cause of Stomach Ulcers

Warning: This document is intended for the scientific community only. Its sole purpose is to disclose test results concerning Bioprin, an herbal formula, as applied to H. Pylori.

SUMMARY: Due to a recent discovery by Dr. Mototsugu Kato and Dr. Masahiro Asaka of Hokkaido University in Japan that was published in the Lancet medical journal, JBNI has just released the anti-H. Pylori (a known cause of stomach ulcers) test report studying their herbal formula for nervous system health and comfort, Bioprin. This comes just after JBNI's last press release disclosing Bioprin's effectiveness on EMT-6, the equivalent of human metastatic breast cancer.

JBNI's Bioprin, their 100% herbal pain reliever, is reported to inhibit H. Pylori (a group I carcinogen for stomach cancer by the World Health Organization) in a clinical study by Food Products Laboratory, Inc. This study enlarges on the previous JBNI press release documenting Bioprin's anti-tumor effectiveness on EMT-6 (human metastatic breast cancer).

While only about 10,000 people die of stomach cancer annually, over 5,000,000 currently suffer from an ulcerated stomach lining, the main cause of stomach cancer. Over a lifetime, 1 in 10 will get a peptic ulcer which is, in turn, caused by H. Pylori.

Upon inhibition of H. Pylori, Dr. Mototsugu Kato and Dr. Masahiro Asaka of Hokkaido University in Japan demonstrated a two thirds lower likelihood of stomach cancer recurrence after initial treatment. To inhibit H. Pylori, Drs. Kato and Asaka used 30 milligrams of lansoprazole twice daily, 750 milligrams of amoxicillin twice daily, and 200 milligrams of clarithromycin twice a day for a week, Health Day news reported.

FPL's test of Bioprin against H. Pylori, FPL states, that Bioprin's testing "may indicate that H. Pylori is destroyed 100% on contact."

The summary impression states: "The inhibitor [Bioprin] is a highly turbid micro-granular natural herb extract. As the concentration increases, inhibition increases exponentially. This may indicate that H. Pylori is destroyed 100% on contact with the inhibitor. Very low inhibition by the clear supernatant of the formula supports this fact because the supernatant contains none or very little herbal extract. 10% supernatant results in 8mm inhibition zone. 10% whole Bioprin results in 30mm inhibition zone which is 10.56 times [greater] inhibition than the supernatant."

"MIC with well assays on TSA with 5% sheep blood" was the test method used. The spec as provided states, "well size: 6mm. Inhibition zones are the diameter including well."

When asked why Bioprin's anti-H. Pylori data was only recently published, Ken Case, JBNI's executive manager, stated, "JBNI wants to keep the message clear that Bioprin is first and foremost an all natural 100% herbal food supplement for nervous system calmness and vigor. It acts just as well to support the ease and comfort of muscles groups and vital organs that are under stress. Granted it tested high in anti-H. Pylori inhibition properties. Granted it shows anti-cancer properties reported by TSRA (Triple S Research Associates) in connection with Dana Farber Cancer Institute / Harvard Medical School. But JBNI's main focus for Bioprin is to safely and naturally deliver ease and comfort by supporting the body's own defense mechanisms."

Azim Walli, JBNI's general manager added, "Our entire line of herbal health formulas have multiple applications. But as with Bioprin, we want to focus on just one application so that the greatest number of people can experience the effectiveness of a purely herbal product. In fact, we don't even recommend that Bioprin be used in any other way than for aches and pains. We only share our test data with other scientists to educate on the potential of herbs."

Mr. Walli welcomes inquiry regarding distribution of JBNI's Bioprin at http://jbni.us/account . JBNI has been making the Bioprin formula broadly available to doctors and physicians for over 20 years. Bioprin has only been available directly to the public since July, 2008.